Cargando…

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

OBJECTIVE: To identify short-term changes in gene expression in peripheral blood mononuclear cells (PBMCs) associated with treatment response to dimethyl fumarate (DMF, Tecfidera) in patients with relapsing-remitting MS (RRMS). METHODS: Blood samples were collected from 24 patients with RRMS (median...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gafson, Arie R., Kim, Kicheol, Cencioni, Maria T., van Hecke, Wim, Nicholas, Richard, Baranzini, Sergio E., Matthews, Paul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168332/ https://www.ncbi.nlm.nih.gov/pubmed/30283812 http://dx.doi.org/10.1212/NXI.0000000000000470

Ejemplares similares

Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate
por: Gafson, Arie R., et al.
Publicado: (2019)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate
por: Sánchez-Sanz, Alicia, et al.
Publicado: (2022)

Dimethyl fumarate alters B‐cell memory and cytokine production in MS patients
por: Smith, Matthew D., et al.
Publicado: (2017)

A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
por: Hillert, Jan, et al.
Publicado: (2021)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients
por: Goldman, Myla D., et al.
Publicado: (2020)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells
por: Staun-Ram, Elsebeth, et al.
Publicado: (2018)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012)

Dimethyl fumarate mitigates optic neuritis
por: Zyla, Katarzyna, et al.
Publicado: (2019)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Drug-Repurposing Strategy for Dimethyl Fumarate
por: Giunta, Salvatore, et al.
Publicado: (2023)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations
por: Fox, Robert J., et al.
Publicado: (2016)

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
por: Sejbaek, Tobias, et al.
Publicado: (2019)

Novel potential pharmacological applications of dimethyl fumarate—an overview and update
por: Bresciani, Giorgia, et al.
Publicado: (2023)

Dimethyl fumarate for treating Papillon–Lefèvre syndrome
por: Al-Omair, Abdullah, et al.
Publicado: (2022)

The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies
por: Manai, Federico, et al.
Publicado: (2022)

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)

Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes
por: Bhargava, Pavan, et al.
Publicado: (2018)

Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis
por: Ferri, Caterina, et al.
Publicado: (2023)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Dimethyl Fumarate Ameliorates Paclitaxel-Induced Neuropathic Pain in Rats
por: Singh, Jagjit, et al.
Publicado: (2022)

Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis
por: Supratak, Akara, et al.
Publicado: (2018)

Interventions to Increase Leukocyte Testing during Treatment with Dimethyl Fumarate
por: Heidenreich, Paul A., et al.
Publicado: (2021)

Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas
por: Ghods, Ali J., et al.
Publicado: (2013)

Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes
por: Huang, He, et al.
Publicado: (2015)

Prevention of Autoimmune Diabetes in NOD Mice by Dimethyl Fumarate
por: Li, Shiri, et al.
Publicado: (2021)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients
por: Lee, Andrew, et al.
Publicado: (2017)

Slowly expanding lesions are a marker of progressive MS – No
por: Arnold, Douglas L, et al.
Publicado: (2021)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma
por: Shafer, Danielle, et al.
Publicado: (2020)

Donor variability may mask dimethyl fumarate’s effects on nuclear factor E2-related factor 2 in human peripheral blood mononuclear cells
por: Fiedler, Sarah E., et al.
Publicado: (2017)

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity
por: Liebmann, Marie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5h37j7tojkohjtblvfia4beaf2